This article is more than 5 years old. Information may no longer be current.
Top 5 diabetes stories, videos posted in the last month
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top five news reports and videos posted from July 25 to Aug. 25.
Healio.com/Endocrinology readers were interested in a fast-track designation for a type 1 diabetes treatment, a new license agreement for an artificial pancreas system, and much more.
FDA fast-track designation granted for type 1 diabetes treatment
The FDA granted a Fast Track designation to Caladrius Biosciences Inc. for its product candidate CLBS03 for the treatment of type 1 diabetes, according to a press release.
The drug previously received an Orphan Drug designation from the FDA and an Advanced Therapeutic Medicinal Product classification from the European Medicines Agency. CLBS03 is currently being tested in a phase 2 clinical trial, The Sanford Project: T-Rex Study; the trial is expected to complete enrollment of the first cohort within the coming weeks. Read more.
Tandem, TypeZero announce license agreement for artificial pancreas system
Tandem Diabetes Care, Inc., and TypeZero Technologies, LLC, have entered into a license agreement allowing Tandem to integrate TypeZero’s artificial pancreas technology into a next-generation t:slim Insulin Pump, according to a press release.
Tandem is a medical device company that manufactures touchscreen insulin pumps. TypeZero is a digital health and personalized medicine company whose artificial pancreas technology includes a series of treat-to-target algorithms. The companies hope to expedite clinical research needed to develop Tandem’s closed-loop artificial pancreas system. Read more.
VIDEO: EMPA-REG, LEADER trial results produce ‘exciting time’ for diabetes care
NEW ORLEANS — The results of the EMPA-REG Outcome study and the LEADER trial have expanded physicians’ armamentariums to be able to decrease patients with diabetes risks for cardiovascular disease, according to Amisha Wallia, MD, MS, of Northwestern Memorial Hospital. Watch video.
Combination of ertugliflozin , sitagliptin superior to monotherapy for lowering HbA1c
NEW ORLEANS — The co-administration of ertugliflozin and sitagliptin was significantly more effective than either therapy alone in reducing HbA1c and fasting plasma glucose in patients with type 2 diabetes who were already on metformin therapy, according to results from the VERTIS Factorial trial presented at the American Diabetes Association Scientific Sessions.
The combination therapy was also more effective in reducing body weight and systolic blood pressure compared with sitagliptin alone, according to the researchers. Read more.
Medtronic launches new user-friendly insulin pump design in US
Medtronic has announced that its MiniMed 360G system with SmartGuard technology has been launched in the United States.
“This latest innovation demonstrates Medtronic’s vision to transform diabetes care to enable greater freedom and better health through a commitment to continually improving both outcomes and user experience,” Alejandro Galindo, president of the intensive insulin management business at Medtronic, said in a press release. Read more.